Skip to main content

IMCD Indonesia strengthens its life science portfolio with the acquisition of PT Megasetia Agung Kimia

Written by Customer Service on . Posted in Mergers And Acquisitions.

Photo – IMCD Indonesia strengthens its life science portfolio with the acquisition of PT Megasetia Agung Kimia

In the picture, Adelia Sia, Managing Director of IMCD Indonesia (left), and Suryani Hartoyo, President Director of Megasetia (right).

In the picture, Adelia Sia, Managing Director of IMCD Indonesia (left), and Suryani Hartoyo, President Director of Megasetia (right).

ROTTERDAM, The Netherlands (17 November 2021) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Indonesia has signed an agreement to acquire 100% of the shares of PT Megasetia Agung Kimia (“Megasetia”) in Indonesia. Megasetia is an excellent fit with IMCD’s life science strategy and provides a significant platform for further growth in the life science segments in Indonesia.

The transaction will take place in two tranches, with IMCD now acquiring 70% of Megasetia’s share capital and the remaining 30% in 2025. The management of Megasetia will continue to lead the company post completion of the first tranche.

Founded in 1995, Megasetia is the leading distributor of speciality ingredients for the pharmaceuticals industry in Indonesia. In addition, it covers the personal care, home care, animal health, and industrial markets, offering end-to-end solutions to its customers and partners with 3 laboratories, 6 offices, and 6 warehouses across Indonesia. Megasetia generated a revenue of approximately IDR 974 billion (ca. EUR 60 million) in 2020 with around 160 employees. It currently serves more than 1,000 customers and represents over 50 of the world’s leading ingredients producers.

“Indonesia is South East Asia’s largest economy and this acquisition provides excellent growth opportunities to strengthen IMCD’s positioning in the life science segments. In addition, it enables us to enhance our offering to local customers and partners,” said Haiko Zuidhoff, Vice President of IMCD APAC.

“We are delighted to be part of IMCD’s global network. We are confident that our life science portfolio will complement their offering to customers and suppliers,” commented Suryani Hartoyo, President Director of Megasetia. “Our culture of growth through market knowledge, technical innovation, and high level of services, is very well aligned with IMCD’s strategy,” concluded Hartoyo.

The closing of the transaction is expected to take place in December 2021.

Attached, please find a pdf format of the press release, the main picture, and its caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.